{
    "clinical_study": {
        "@rank": "33700", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. It is not yet known whether receiving cisplatin with\n      raltitrexed is more effective than cisplatin alone for malignant mesothelioma.\n\n      PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or\n      without raltitrexed in treating patients who have malignant mesothelioma of the pleura."
        }, 
        "brief_title": "Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura", 
        "condition": "Malignant Mesothelioma", 
        "condition_browse": {
            "mesh_term": "Mesothelioma"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Compare overall survival in patients with malignant pleural mesothelioma treated with\n           raltitrexed with or without cisplatin.\n\n        -  Assess toxicity, progression free survival, and quality of life with these treatment\n           regimens in these patients.\n\n        -  Evaluate objective response and duration of response to these treatment regimens in\n           patients with measurable disease.\n\n      OUTLINE: This is a randomized, open, multicenter study. Patients are stratified according to\n      performance status (0 vs 1-2) and WBC count (less than 8,300/mm3 vs 8,300/mm3 or more).\n      Patients are randomized to one of two treatment arms.\n\n        -  Arm I: Patients receive cisplatin IV over 1-2 hours on day 1.\n\n        -  Arm II: Patients receive raltitrexed IV over 15 minutes followed by cisplatin IV over\n           1-2 hours on day 1.\n\n      Treatment continues every 3 weeks in the absence of disease progression or unacceptable\n      toxicity.\n\n      Quality of life is assessed before study, prior to each course, after the last course, and\n      then every 6 weeks for 1 year.\n\n      Patients are followed every 6 weeks until death.\n\n      PROJECTED ACCRUAL: A total of 240 patients will be accrued for this study over 24 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed malignant pleural mesothelioma\n\n          -  No CNS metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Over 18\n\n        Performance status:\n\n          -  ZUBROD, ECOG, WHO 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Hemoglobin at least 10.0 g/dL\n\n          -  WBC at least 4,000/mm^3\n\n          -  Absolute neutrophil count at least 2,000/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin less than 1.46 mg/dL\n\n          -  Albumin at least 3.0 g/dL\n\n          -  ALAT/ASAT less than 2.5 times upper limit of normal (ULN) (less than 5 times ULN if\n             liver involvement)\n\n        Renal:\n\n          -  Creatinine less than 1.69 mg/dL\n\n          -  Creatinine clearance at least 65 mL/min\n\n        Cardiovascular:\n\n          -  Not specified\n\n        Pulmonary:\n\n          -  Not specified\n\n        Other:\n\n          -  No other prior or concurrent malignancies within past 5 years except adequately\n             treated carcinoma in situ of the cervix or basal or squamous cell carcinoma of the\n             skin\n\n          -  No prior malignant melanoma, hypernephroma or breast carcinoma\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception during and for 6 months after study\n\n          -  No uncontrolled infections\n\n          -  No psychological, familial, sociological, or geographical condition that precludes\n             study compliance\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No concurrent immunotherapy before first disease progression\n\n        Chemotherapy:\n\n          -  No prior systemic or intracavitary cytotoxic chemotherapy\n\n          -  No other prior or concurrent chemotherapy before first disease progression\n\n          -  No prior or concurrent pleurodesis with cytotoxic drugs (e.g., bleomycin)\n\n        Endocrine therapy:\n\n          -  No concurrent hormonal therapy except corticosteroids before first disease\n             progression\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy to target lesion and progression observed\n\n          -  Concurrent palliative radiotherapy to painful lesions allowed only if target lesion\n             outside of irradiated field\n\n        Surgery:\n\n          -  Prior surgery allowed if followed by disease progression\n\n        Other:\n\n          -  At least 1 month since prior investigational drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "256", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 7, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004920", 
            "org_study_id": "EORTC-08983", 
            "secondary_id": "EORTC-08983"
        }, 
        "intervention": [
            {
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "raltitrexed", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Raltitrexed", 
                "Cisplatin"
            ]
        }, 
        "keyword": [
            "localized malignant mesothelioma", 
            "advanced malignant mesothelioma", 
            "recurrent malignant mesothelioma"
        ], 
        "lastchanged_date": "July 17, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-08983"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "B-3000"
                    }, 
                    "name": "U.Z. Gasthuisberg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 5C2"
                    }, 
                    "name": "Cancer Care Ontario-Hamilton Regional Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 4L6"
                    }, 
                    "name": "Cancer Care Ontario-London Regional Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mississauga", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L5B 1B8"
                    }, 
                    "name": "Trillium Health Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Princess Margaret Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2W 1S6"
                    }, 
                    "name": "McGill University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Regina", 
                        "country": "Canada", 
                        "state": "Saskatchewan", 
                        "zip": "S4T 7T1"
                    }, 
                    "name": "Allan Blair Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cairo", 
                        "country": "Egypt"
                    }, 
                    "name": "National Cancer Institute of Egypt"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13274"
                    }, 
                    "name": "Assistance Publique Hopitaux de Marseille Hopitaux Sud"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13385"
                    }, 
                    "name": "Hopital de la Conception"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "76031"
                    }, 
                    "name": "Hopital Charles Nicolle"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "D-69126"
                    }, 
                    "name": "Thoraxklinik Rohrbach"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genoa (Genova)", 
                        "country": "Italy", 
                        "zip": "16132"
                    }, 
                    "name": "Istituto Nazionale per la Ricerca sul Cancro"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands", 
                        "zip": "NL-6500 HB"
                    }, 
                    "name": "University Medical Center Nijmegen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3075 EA"
                    }, 
                    "name": "Erasmus Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3000 CA"
                    }, 
                    "name": "University Hospital - Rotterdam Dijkzigt"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584 CX"
                    }, 
                    "name": "Academisch Ziekenhuis Utrecht"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lima", 
                        "country": "Peru", 
                        "zip": "34"
                    }, 
                    "name": "Instituto de Enfermedades Neoplasicas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gdansk", 
                        "country": "Poland", 
                        "zip": "80-211"
                    }, 
                    "name": "Medical University of Gdansk"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poznan", 
                        "country": "Poland", 
                        "zip": "60 569"
                    }, 
                    "name": "Regional Lung Diseases Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland", 
                        "zip": "CH-4031"
                    }, 
                    "name": "University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland", 
                        "zip": "CH-3010"
                    }, 
                    "name": "Inselspital, Bern"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland", 
                        "zip": "CH-9007"
                    }, 
                    "name": "Kantonsspital - St. Gallen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "NG5 1PB"
                    }, 
                    "name": "Nottingham City Hospital NHS Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "S1O 2SJ"
                    }, 
                    "name": "Weston Park Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom", 
                        "state": "Scotland", 
                        "zip": "EH4 2XU"
                    }, 
                    "name": "Western General Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Canada", 
                "Egypt", 
                "France", 
                "Germany", 
                "Italy", 
                "Netherlands", 
                "Peru", 
                "Poland", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "official_title": "Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma", 
        "overall_official": {
            "affiliation": "University Medical Center Rotterdam at Erasmus Medical Center", 
            "last_name": "Jan P. Van Meerbeeck, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2003", 
            "@type": "Actual"
        }, 
        "reference": {
            "PMID": "16809726", 
            "citation": "Francart J, Legrand C, Sylvester R, Van Glabbeke M, van Meerbeeck JP, Robert A. Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group. J Clin Oncol. 2006 Jul 1;24(19):3007-12."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004920"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "18089874", 
                "citation": "Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, van Meerbeeck JP; EORTC-NCIC. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol. 2007 Dec 20;25(36):5770-6."
            }, 
            {
                "PMID": "16446322", 
                "citation": "Bottomley A, Gaafar R, Manegold C, Burgers S, Coens C, Legrand C, Vincent M, Giaccone G, Van Meerbeeck J; EORTC Lung-Cancer Group; National Cancer Institute, Canada. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol. 2006 Mar 20;24(9):1435-42. Epub 2006 Jan 30. Erratum in: J Clin Oncol. 2006 Jun 1;24(16):2601. Gaafa, Rabab [corrected to Gaafar, Rahab]."
            }, 
            {
                "PMID": "16192580", 
                "citation": "van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G; European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005 Oct 1;23(28):6881-9."
            }, 
            {
                "citation": "Van Meerbeeck JP, Manegold C, Gaafar R, et al.: A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC. [Abstract] J Clin Oncol 22 (Suppl 14): A-7021, 622s, 2004."
            }
        ], 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 1999", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }, 
    "geocoordinates": {
        "Academisch Ziekenhuis Utrecht": "52.09 5.11", 
        "Allan Blair Cancer Centre": "50.455 -104.607", 
        "Assistance Publique Hopitaux de Marseille Hopitaux Sud": "43.296 5.37", 
        "Cancer Care Ontario-Hamilton Regional Cancer Centre": "43.244 -79.889", 
        "Cancer Care Ontario-London Regional Cancer Centre": "42.979 -81.246", 
        "Erasmus Medical Center": "51.924 4.482", 
        "Hopital Charles Nicolle": "49.443 1.1", 
        "Hopital de la Conception": "43.296 5.37", 
        "Inselspital, Bern": "46.948 7.445", 
        "Instituto de Enfermedades Neoplasicas": "-12.093 -77.046", 
        "Istituto Nazionale per la Ricerca sul Cancro": "44.407 8.934", 
        "Kantonsspital - St. Gallen": "47.424 9.371", 
        "McGill University": "45.509 -73.554", 
        "Medical University of Gdansk": "54.352 18.647", 
        "National Cancer Institute of Egypt": "30.044 31.236", 
        "Nottingham City Hospital NHS Trust": "52.955 -1.158", 
        "Princess Margaret Hospital": "43.653 -79.383", 
        "Regional Lung Diseases Hospital": "52.406 16.925", 
        "Thoraxklinik Rohrbach": "49.399 8.672", 
        "Trillium Health Centre": "43.589 -79.644", 
        "U.Z. Gasthuisberg": "50.878 4.704", 
        "University Hospital": "47.557 7.593", 
        "University Hospital - Rotterdam Dijkzigt": "51.924 4.482", 
        "University Medical Center Nijmegen": "51.843 5.855", 
        "Western General Hospital": "55.953 -3.188", 
        "Weston Park Hospital": "53.381 -1.47"
    }
}